Alecensa (Alectinib) 150mg Capsules 224 Multipack | Roche USA for ALK+ NSCLC | GLT

Generic Information: Alecensa (Alectinib) — United States Version

Alecensa hard capsules are the original Roche/Genentech presentation of alectinib, the medicine that reset the standard of care for ALK-positive non-small cell lung cancer. The US shelf pack is a multipack of 224 capsules of 150 mg — four wallet packs of 56 — sized to one treatment cycle at the approved schedule. Under the skin of an ordinary looking capsule sits one of the most clinically consequential molecules in modern lung oncology: a brain-penetrant, second-generation ALK inhibitor that also suppresses RET kinase in laboratory models.

What Is Alecensa (Alectinib) Used For?

US oncologists reach for Alecensa in three situations: as initial (first-line) therapy for metastatic ALK-positive NSCLC confirmed by an FDA-approved companion diagnostic; for disease that progressed after crizotinib; and, since the adjuvant label was granted, to reduce recurrence risk after resection of ALK-positive tumors of at least 4 cm or with involved nodes. International buyers ask GLT for the US presentation chiefly for continuity of supply when local channels are strained.

How Does Alecensa (Alectinib) Work?

The ALK rearrangement fuses part of the ALK gene to a partner gene, creating a permanently switched-on growth signal. Alectinib slots into the ALK kinase pocket — including several crizotinib-resistance conformations — and closes the signal down. Because it evades the efflux pumps that pump drugs out of the central nervous system, it holds intracranial disease in check, which is the property that separated it from its predecessor in head-to-head study. Its major metabolite M4 is itself active, and both parent and metabolite linger long enough (terminal half-lives around 30-plus hours) to support twice-daily dosing.

Indications of Alecensa (US Label)

The FDA label reads: first-line treatment of ALK-positive metastatic NSCLC (detected by an approved test); ALK-positive metastatic NSCLC after progression on or intolerance of crizotinib; and adjuvant treatment following tumor resection in ALK-positive NSCLC of 4 cm or larger or node-positive. Each indication carries the same precondition — a validated ALK result — and none extend to ALK-negative disease, where alectinib has no role.

Dosage and Administration

Four capsules (600 mg) twice daily with food — morning and evening about twelve hours apart — is the standing dose, giving exactly 28 days of therapy per 224-capsule multipack. Severe hepatic impairment (Child-Pugh C) starts lower, at 450 mg twice daily. Toxicity-driven reductions move 600 → 450 → 300 mg twice daily, with permanent discontinuation if even the lowest step is not tolerated. Capsules stay whole; a missed dose is taken as soon as remembered unless fewer than six hours remain before the next one.

Side Effects of Alecensa (Alectinib)

The US label's most common reactions are constipation, edema, myalgia, nausea, fatigue, anemia and rash. The label's boxed-level vigilance items are hepatotoxicity, interstitial lung disease/pneumonitis, symptomatic bradycardia, severe CPK elevation with muscle injury, hemolytic anemia and embryo-fetal toxicity — each with a defined withhold-or-discontinue pathway. Practical monitoring in US practice: liver panel and CPK every two weeks early on, heart rate and blood pressure routinely, and firm sun-protection counseling because photosensitivity develops quickly.

Storage Instructions

Store at 20°C–25°C with excursions permitted in the original packaging, protected from moisture; use an opened wallet pack within its labeled in-use window. Keep away from children and return unused medicine to a take-back point.

Why Choose Alecensa (US) from GLT?

For buyers who specifically want the US-originator presentation — sealed Roche/Genentech multipack, English labeling, US batch records — GLT sources through verified channels and ships with documentation that hospital pharmacies and customs brokers recognize. The honest caveat we give every enquirer: US list pricing for this medicine sits at the top of the global range, and most of our clients compare it against the identical Roche packs from other regulated markets or against certified generics from Bangladesh and Laos, which typically run roughly 70%–80% below the US list price for the same monthly course. You get straight numbers and batch proof either way — just ask on WhatsApp +86 15234153837 or at [email protected].

How to Order Alecensa (Alectinib)

The GLT workflow is deliberately short: enquire with product and quantity, receive a formal quotation with shipping and payment options, confirm, and we dispatch with full export documentation. Contact WhatsApp +86 15234153837 or email [email protected]; institutions can request CoA and batch images before payment, and standing monthly orders are welcome.

FAQ

Why is the US pack 224 capsules? Because the approved schedule uses eight capsules a day, 224 equals a 28-day cycle — one box, one month.

Is there a cheaper route to the same molecule? Yes — the same Roche packs exist in other regulated markets, and WHO-GMP generics (Alecnib, Alynni, LuciAle, Ailedx) are listed on our site; we will quote them side by side.

Does food really matter with alectinib? It matters a lot — absorption rises substantially with a meal, so every dose goes down with food.

What if I miss a dose? Take it when you remember unless the next dose is under six hours away; never double up.

Can you supply documentation for institutional import? Yes — batch records, CoA copies and the standard export set are available on request before you commit.